A veterinary florfenicol solution, its preparation method and application

Abstract

The present invention provides a florfenicol solution for veterinary use, its preparation method and application. In the florfenicol solution for veterinary use, the mass percentage of florfenicol is 20% - 35%, the mass percentage of the complexing agent is 6% - 15%, the mass percentage of the cosolvent is 5% - 10%, the mass percentage of the solubilizer is 10% - 15%, the mass percentage of the wetting agent is 0.05% - 0.2%, the mass percentage of the pH regulator is 0.8% - 1.5%, the mass percentage of the antioxidant is 0.8% - 2.5%, and the mass percentage of the flavoring agent is 1.0% - 5.0%. The preparation process of the florfenicol solution for veterinary use in the present invention is simple, the solubility of florfenicol is good, the solution is clear, and there is no precipitation after long-term storage. The test results show that the florfenicol solution for veterinary use in the present invention has a significant therapeutic effect on chicken colibacillosis, can effectively control the symptoms of swine enzootic pneumonia, and improve the mental state and respiratory rate.

Description

Technical Field

[0001] The present invention relates to the technical field of veterinary drugs, and particularly relates to a veterinary florfenicol solution, a preparation method thereof, and an application thereof. Background Art

[0002] Florfenicol, also known as florfenicolum, is a special antibacterial drug for animals of the class of phenicols. It has been widely used in the breeding industry in China. This drug was developed by Schering-Plough Corporation of the United States in the late 1970s. It is obtained by replacing the hydroxyl group at the 3-carbon position of the propane chain in thiamphenicol with a fluorine atom, and is an upgraded product of chloramphenicol and thiamphenicol. Since chloramphenicol has serious adverse reactions on the hematopoietic system, it is less used; while florfenicol has no potential effects of causing aplastic anemia, teratogenesis, carcinogenesis, and mutagenesis. Its antibacterial spectrum and antibacterial activity are superior to those of chloramphenicol and thiamphenicol, up to 10 times that of thiamphenicol, and it still has antibacterial activity against bacteria resistant to chloramphenicol and thiamphenicol, showing broad application prospects.

[0003] As a new type of antibiotic for animals, especially for antibacterial, mycoplasma, and thiamphenicol-resistant bacteria, florfenicol is often used to treat diseases caused by streptococcus. It has no residue or low residue in the body and is extremely widely used in clinical applications.

[0004] Florfenicol can be used to treat swine contagious pleuropneumonia caused by Actinobacillus pleuropneumoniae in pigs. In Japan and Mexico, it is mainly used for the prevention and treatment of swine bacterial diseases and is also used as a swine feed premix.

[0005] Florfenicol has poor water solubility and low bioavailability, which limits the exertion of its drug effect and brings inconvenience to clinical use. At present, the main preparations of florfenicol include 4 dosage forms such as injection, soluble powder, solution, and premix. The application purposes of different preparations are different, and the curative effects also have certain differences. Summary of the Invention

[0006] The present invention aims to provide a veterinary florfenicol solution, a preparation method thereof, and an application thereof.

[0007] To achieve the above object, the present invention adopts the following technical solutions:

[0008] In the first aspect of the present invention, there is provided a veterinary florfenicol solution, which is composed of the following components: florfenicol, a complexing agent, a cosolvent, a solubilizer, a wetting agent, a pH regulator, an antioxidant, and a flavoring agent.

[0009] Preferably, in the florfenicol solution for veterinary use of the present invention, the mass percentage of florfenicol is 20% - 35%, the mass percentage of the complexing agent is 6% - 15%, the mass percentage of the co-solvent is 5% - 10%, the mass percentage of the solubilizer is 10% - 15%, the mass percentage of the wetting agent is 0.05% - 0.2%, the mass percentage of the pH regulator is 0.8% - 1.5%, the mass percentage of the antioxidant is 0.8% - 2.5%, and the mass percentage of the flavoring agent is 1.0% - 5.0%.

[0010] Preferably, the complexing agent is hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:1 - 3:2 - 5.

[0011] Preferably, the co-solvent is propylene glycol and polyethylene glycol 400 with a mass ratio of 1:2 - 4.

[0012] Preferably, the solubilizer is hydroxypropyl methylcellulose.

[0013] Preferably, the wetting agent is dextran or ammonium alginate.

[0014] Preferably, the pH regulator is lactic acid - sodium lactate.

[0015] Preferably, the antioxidant is sodium metabisulfite.

[0016] Preferably, the flavoring agent is maltitol.

[0017] A preferred formulation of the present invention is: 25 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hydroxypropyl methylcellulose, 0.1 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite and 3.0 g of maltitol.

[0018] Another preferred formulation of the present invention is: 25 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hydroxypropyl methylcellulose, 0.1 g of ammonium alginate, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite and 3.0 g of maltitol.

[0019] In the second aspect of the present invention, a preparation method of the above-mentioned florfenicol solution for veterinary use is provided, including the following steps:

[0020] Under stirring conditions, dissolve the co-solvent in water, add the antioxidant and flavoring agent to obtain mixture 1; at a temperature of 45°C to 55°C, mix florfenicol evenly with the wetting agent, complexing agent, and solubilizer to obtain mixture 2; mix mixture 1 and mixture 2, let it cool, and defoam; add a pH regulator to adjust the pH of the solution to 6.0 - 7.0 to obtain the veterinary florfenicol solution.

[0021] Preferably, the temperature is 50°C.

[0022] Preferably, the pH of the florfenicol solution is 6.5.

[0023] In the third aspect of the present invention, there is provided the use of the above-mentioned veterinary florfenicol solution in the preparation of veterinary drugs.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] The preparation process of the veterinary florfenicol solution of the present invention is simple, the solubility of florfenicol is good, the solution is clear, and there is no precipitation after long-term storage.

[0026] The florfenicol solution of the present invention has a significant therapeutic effect on chicken colibacillosis. The veterinary florfenicol solution of the present invention can effectively control the symptoms of swine enzootic pneumonia and improve the mental state and respiratory rate. Specific embodiments

[0028] The following further details the content of the present invention through specific embodiments, but this should not be construed as limiting the scope of the above-mentioned subject matter of the present invention to the following embodiments. The following embodiments are used to illustrate the technical solutions of the present invention rather than to limit the protection scope of the present invention. Those of ordinary skill in the art who modify or equivalently replace the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention still fall within the protection scope of the present invention.

[0029] Example 1

[0030] A veterinary florfenicol solution is prepared by the following method:

[0031] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hypromellose, 0.1 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite, and 3.0 g of maltitol.

[0032] Under stirring conditions, dissolve propylene glycol and polyethylene glycol 400 in water, add sodium metabisulfite and maltitol to obtain mixture 1; at 50 °C, mix florfenicol, dextran, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, β-cyclodextrin, and hypromellose uniformly to obtain mixture 2; mix mixture 1 and mixture 2, let it cool, and defoam; add lactic acid-sodium lactate to adjust the pH of the solution to 6.5 to obtain the veterinary florfenicol solution.

[0033] Example 2

[0034] A veterinary florfenicol solution is prepared by the following method:

[0035] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hypromellose, 0.1 g of ammonium alginate, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite, and 3.0 g of maltitol.

[0036] Under stirring conditions, dissolve propylene glycol and polyethylene glycol 400 in water, add sodium metabisulfite and maltitol to obtain mixture 1; at 45 °C, mix florfenicol, ammonium alginate, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, β-cyclodextrin, and hypromellose uniformly to obtain mixture 2; mix mixture 1 and mixture 2, let it cool, and defoam; add lactic acid-sodium lactate to adjust the pH of the solution to 6.0 to obtain the veterinary florfenicol solution.

[0037] Example 3

[0038] A veterinary florfenicol solution is prepared by the following method:

[0039] 25 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, and β-cyclodextrin with a mass ratio of 1:3:5, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:2, 15 g of hypromellose, 0.05 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 2.5 g of sodium metabisulfite, and 2.0 g of maltitol.

[0040] Under stirring conditions, dissolve propylene glycol and polyethylene glycol 400 in water, add sodium metabisulfite and maltitol to obtain mixture 1; at 55 °C, mix florfenicol, dextran, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, β-cyclodextrin, and hypromellose uniformly to obtain mixture 2; mix mixture 1 and mixture 2, let it cool, and defoam; add lactic acid-sodium lactate to adjust the pH of the solution to 7.0 to obtain the veterinary florfenicol solution.

[0041] Example 4

[0042] A veterinary florfenicol solution is prepared by the following method:

[0043] 20 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:1:2, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:4, 10 g of hypromellose, 0.05 g of ammonium alginate, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 0.8 g of sodium metabisulfite and 3.0 g of maltitol.

[0044] Under stirring conditions, dissolve propylene glycol and polyethylene glycol 400 in water, add sodium metabisulfite and maltitol to obtain mixture 1; at 45 °C, mix florfenicol and ammonium alginate, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin, and hypromellose evenly to obtain mixture 2; mix mixture 1 and mixture 2, cool, and defoam; add lactic acid-sodium lactate to adjust the pH of the solution to 6.8 to obtain the veterinary florfenicol solution.

[0045] Example 5

[0046] A veterinary florfenicol solution is prepared by the following method:

[0047] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:4, 12 g of hypromellose, 0.2 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 2.0 g of sodium metabisulfite and 5.0 g of maltitol.

[0048] Under stirring conditions, dissolve propylene glycol and polyethylene glycol 400 in water, add sodium metabisulfite and maltitol to obtain mixture 1; at 50 °C, mix florfenicol and dextran, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin, and hypromellose evenly to obtain mixture 2; mix mixture 1 and mixture 2, cool, and defoam; add lactic acid-sodium lactate to adjust the pH of the solution to 6.0 to obtain the veterinary florfenicol solution.

[0049] Example 6

[0050] A veterinary florfenicol solution is prepared by the following method:

[0051] 35 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:3:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:2, 15 g of hypromellose, 0.2 g of ammonium alginate, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite and 1.0 g of maltitol.

[0052] Under stirring conditions, dissolve propylene glycol and polyethylene glycol 400 in water, add sodium metabisulfite and maltitol to obtain mixture 1; at 55 °C, mix florfenicol, ammonium alginate, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, β-cyclodextrin, and hypromellose evenly to obtain mixture 2; mix mixture 1 and mixture 2, let it cool, and defoam; add lactic acid-sodium lactate to adjust the pH of the solution to 7.0 to obtain the veterinary florfenicol solution.

[0053] Comparative Example 1

[0054] Prepared by the following method:

[0055] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, and β-cyclodextrin with a mass ratio of 1:4:6, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hypromellose, 0.1 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite, and 3.0 g of maltitol.

[0056] The preparation method refers to Example 1.

[0057] Compared with Example 1, the difference in this comparative example is the different dosages of each component of the complexing agent.

[0058] Comparative Example 2

[0059] Prepared by the following method:

[0060] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hypromellose, 0.1 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite, and 3.0 g of maltitol.

[0061] The preparation method refers to Example 1.

[0062] Compared with Example 1, the difference in this comparative example is the different types of complexing agents.

[0063] Comparative Example 3

[0064] Prepared by the following method:

[0065] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin, and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of ethanol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hypromellose, 0.1 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite, and 3.0 g of maltitol.

[0066] The preparation method refers to Example 1.

[0067] Compared with Example 1, the difference in this comparative example lies in the different types of cosolvents.

[0068] Comparative Example 4

[0069] It is prepared by the following method:

[0070] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of Tween 80, 0.1 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite and 3.0 g of maltitol.

[0071] The preparation method refers to Example 1.

[0072] Compared with Example 1, the difference in this comparative example lies in the different types of solubilizers.

[0073] Comparative Example 5

[0074] It is prepared by the following method:

[0075] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hypromellose, 0.1 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of vitamin C and 3.0 g of maltitol.

[0076] The preparation method refers to Example 1.

[0077] Compared with Example 1, the difference in this comparative example lies in the different types of antioxidants.

[0078] Comparative Example 6

[0079] It is prepared by the following method:

[0080] 30 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hypromellose, 0.1 g of dextran, 0.93 mg of citric acid, 1.0 g of sodium citrate, 1.5 g of sodium metabisulfite and 3.0 g of maltitol.

[0081] The preparation method refers to Example 1.

[0082] Compared with Example 1, the difference in this comparative example lies in the different types of pH regulators.

[0083] Physical experiment: solubility stability in water

[0084] Samples of Example 1, Example 2, Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, Comparative Example 5, and Comparative Example 6 were dissolved in water at a ratio of 1:300 and placed at room temperature for 6 h, 12 h, 18 h, and 24 h to examine the precipitation situation. The test results are shown in Table 1.

[0085] Table 1 Solubility stability at room temperature

[0086]

[0087] Effect Example 1 Test of the solution of florfenicol for veterinary use of the present invention in the treatment of avian colibacillosis

[0088] 400 Hy-Line Brown chickens diagnosed with colibacillosis were divided into 8 groups, with 50 chickens in each group, namely Administration Group 1, Administration Group 2, Administration Group 3, Administration Group 4, Administration Group 5, Administration Group 6, Administration Group 7, and Administration Group 8.

[0089] Administration Group 1 was administered the solution of florfenicol for veterinary use of Example 1 by drinking water at a dose of 0.2 mL / L; Administration Group 2 was administered the solution of florfenicol for veterinary use of Example 2 by drinking water at a dose of 0.2 mL / L; Administration Group 3 was administered the sample of Comparative Example 1 by drinking water at a dose of 0.2 mL / L; Administration Group 4 was administered the sample of Comparative Example 2 by drinking water at a dose of 0.2 mL / L; Administration Group 5 was administered the sample of Comparative Example 3 by drinking water at a dose of 0.2 mL / L; Administration Group 6 was administered the sample of Comparative Example 4 by drinking water at a dose of 0.2 mL / L; Administration Group 7 was administered the sample of Comparative Example 5 by drinking water at a dose of 0.2 mL / L; Administration Group 8 was administered the sample of Comparative Example 6 by drinking water at a dose of 0.2 mL / L.

[0090] 10 days after drug treatment, various clinical manifestations and death situations of the chickens were observed and recorded every day.

[0091] Table 2 Therapeutic effect of the solution of florfenicol for veterinary use of the present invention on avian colibacillosis

[0092]

[0093] The effective rates of Administration Group 1 and Administration Group 2 were 98.0% and 96.0% respectively; the effects of Administration Group 1 and Administration Group 2 in treating avian colibacillosis were better than those of Administration Group 3, Administration Group 4, Administration Group 5, Administration Group 6, Administration Group 7, and Administration Group 8.

[0094] The test results show that the solution of florfenicol for veterinary use of the present invention has a significant therapeutic effect on avian colibacillosis.

[0095] Effect Example 2 Clinical trial of the solution of florfenicol for veterinary use of the present invention in the treatment of swine enzootic pneumonia

[0096] 240 diseased pigs determined to be suffering from asthma were divided into 8 groups, with 30 pigs in each group: Administration Group 1, Administration Group 2, Administration Group 3, Administration Group 4, Administration Group 5, Administration Group 6, Administration Group 7, and Administration Group 8.

[0097] Administration Group 1 was given drinking water containing 0.8 mL / L of the florfenicol solution for veterinary use in Example 1; Administration Group 2 was given drinking water containing 0.8 mL / L of the florfenicol solution for veterinary use in Example 2; Administration Group 3 was given drinking water containing 0.8 mL / L of the sample in Comparative Example 1; Administration Group 4 was given drinking water containing 0.8 mL / L of the sample in Comparative Example 2; Administration Group 5 was given drinking water containing 0.8 mL / L of the sample in Comparative Example 3; Administration Group 6 was given drinking water containing 0.8 mL / L of the sample in Comparative Example 4; Administration Group 7 was given drinking water containing 0.8 mL / L of the sample in Comparative Example 5; Administration Group 8 was given drinking water containing 0.8 mL / L of the sample in Comparative Example 6.

[0098] 4 days after drug treatment, the respiratory conditions of the pigs in each group were recorded, including appetite, asthma, and cough, and their mental states were scored. Recovery: Asthma and cough completely disappeared, appetite, mental state, and breathing were normal, and there were no signs of recurrence. Effective: Asthma and cough improved, appetite, mental state, and breathing returned to normal, and there were no signs of recurrence. Ineffective: Asthma and cough did not completely disappear, and there were no obvious changes or signs of aggravation in appetite, mental state, and breathing. Effective rate = (cured + effective) / total number of cases × 100%, and comparisons were made after calculation.

[0099] The test results are shown in Table 3 and Table 4.

[0100] Table 3 Therapeutic effects of the florfenicol solution for veterinary use of the present invention on swine enzootic pneumonia

[0101]

[0102] The effective rates of Administration Group 1 and Administration Group 2 were 98.0% and 96.0% respectively; the effects of Administration Group 1 and Administration Group 2 in treating swine enzootic pneumonia were better than those of Administration Group 3, Administration Group 4, Administration Group 5, Administration Group 6, Administration Group 7, and Administration Group 8.

[0103] Table 4 Effects of the florfenicol solution for veterinary use of the present invention on the mental state and respiratory rate of swine enzootic pneumonia

[0104]

[0105] The florfenicol solution for veterinary use of the present invention can effectively control the symptoms of swine enzootic pneumonia and improve the mental state and respiratory rate. The therapeutic effects of Example 1 Group and Example 2 Group are significantly better than those of the comparative example groups.

[0106] The above embodiments are not any formal limitations on the present invention. For those skilled in the art, any modifications, substitutions, etc. made within the scope of the technical essence of the present invention and within the scope of the technical solution of the present invention still fall within the protection scope of the technical solution of the present invention.

Claims

1. A florfenicol solution for veterinary use, characterized in that, The veterinary florfenicol solution consists of the following components: florfenicol, complexing agent, cosolvent, solubilizer, wetting agent, pH regulator, antioxidant, flavoring agent and water; The mass percentage of florfenicol is 20%-35%, the mass percentage of complexing agent is 6%-15%, the mass percentage of cosolvent is 5%-10%, the mass percentage of solubilizer is 10%-15%, the mass percentage of wetting agent is 0.05%-0.2%, the mass percentage of pH regulator is 0.8%-1.5%, the mass percentage of antioxidant is 0.8%-2.5%, the mass percentage of flavoring agent is 1.0%-5.0%, and the balance is water; The complexing agent is hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:1-3:2-5; The cosolvent is propylene glycol and polyethylene glycol 400 with a mass ratio of 1:2-4; The solubilizer is hypromellose; The wetting agent is dextran or ammonium alginate; the pH regulator is lactic acid-sodium lactate; the antioxidant is sodium metabisulfite; the flavoring agent is maltitol; The veterinary florfenicol solution includes 25 g of florfenicol, 10 g of hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and β-cyclodextrin with a mass ratio of 1:2:4, 8 g of propylene glycol and polyethylene glycol 400 with a mass ratio of 1:3, 12 g of hypromellose, 0.1 g of dextran, 0.93 mg of lactic acid, 1.0 g of sodium lactate, 1.5 g of sodium metabisulfite and 3.0 g of maltitol.

2. The florfenicol solution for veterinary use according to claim 1, characterized in that, The preparation method of the veterinary florfenicol includes the following steps: under stirring conditions, dissolve the cosolvent in water, add the antioxidant and flavoring agent to obtain mixture 1; at a temperature of 45°C to 55°C, mix florfenicol with the wetting agent, complexing agent and solubilizer evenly to obtain mixture 2; mix mixture 1 and mixture 2, cool, and defoam; add the pH regulator to adjust the pH of the solution to 6.0-7.0 to obtain the veterinary florfenicol solution.

3. The application of the veterinary florfenicol solution according to claim 1 in the preparation of veterinary drugs.

Images